Literature DB >> 2170392

Carbohydrate-binding protein 35. Isoelectric points of the polypeptide and a phosphorylated derivative.

E A Cowles1, N Agrwal, R L Anderson, J L Wang.   

Abstract

Purified carbohydrate-binding protein 35 (CBP35) and extracts of mouse cells containing CBP35 were analyzed by two-dimensional gel electrophoresis. Such an analysis on recombinant CBP35, obtained by expression of a cDNA clone in Escherichia coli, yielded a pI value of 8.7. When extracts of mouse 3T3 cells were subjected to two-dimensional gel electrophoresis and immunoblotting, two spots were observed, corresponding to pI values of 8.7 and 8.2. The pI 8.2 species represents post-translational modification of the CBP35 polypeptide (pI 8.7) by the addition of a single phosphate group. This conclusion is based on the finding that purified CBP35 contained a pI 8.2 species that was labeled with 32PO4 and could be converted to the unlabeled pI 8.7 species by alkaline phosphatase treatment. The phosphorylated (pI 8.2) form of CBP35 is found in both the cytosolic and nuclear fractions, whereas the unphosphorylated (pI 8.7) species is found exclusively in the nuclei. Quiescent populations of 3T3 fibroblasts (confluent monolayers or serum-starved sparse cultures) are characterized by the predominance of phosphorylated CBP35. Stimulation of the same cells into the proliferative state resulted in an increase in the amount of the phosphorylated species; more dramatic, however, is the elevation of the level of the unphosphorylated form, which is barely detectable in quiescent cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170392

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Expression of galectin-3 modulates T-cell growth and apoptosis.

Authors:  R Y Yang; D K Hsu; F T Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation.

Authors:  E Lippert; M Gunckel; J Brenmoehl; F Bataille; W Falk; J Scholmerich; F Obermeier; G Rogler
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

4.  The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells.

Authors:  Victor L Thijssen; Sarah Hulsmans; Arjan W Griffioen
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

Review 5.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

Review 6.  Galectin-3 and the skin.

Authors:  Larissa Larsen; Huan-Yuan Chen; Jun Saegusa; Fu-Tong Liu
Journal:  J Dermatol Sci       Date:  2011-08-11       Impact factor: 4.563

7.  Evidence for a role for galectin-1 in pre-mRNA splicing.

Authors:  A Vyakarnam; S F Dagher; J L Wang; R J Patterson
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

8.  Galectin-3: differential accumulation of distinct mRNAs in serum-stimulated mouse 3T3 fibroblasts.

Authors:  P G Voss; Y G Tsay; J L Wang
Journal:  Glycoconj J       Date:  1994-08       Impact factor: 2.916

9.  Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma.

Authors:  M M Lotz; C W Andrews; C A Korzelius; E C Lee; G D Steele; A Clarke; A M Mercurio
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

10.  Galectin-3 is associated with prostasomes in human semen.

Authors:  Jennifer L Jones; Sarika Saraswati; Ashley S Block; Cheryl F Lichti; Maha Mahadevan; Alan B Diekman
Journal:  Glycoconj J       Date:  2009-10-15       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.